PROTAC: Harnessing Targeted Chimeras for Selective BCL-2 Degradation in Cancer Treatment.
Sign Up to like & getrecommendations! Published in 2023 at "ACS medicinal chemistry letters"
DOI: 10.1021/acsmedchemlett.3c00113
Abstract: The anti-apoptotic BCL-2 protein family members, including BCL-2, BCL-XL, and MCL-1, have been established as promising therapeutic targets for cancer treatment, as evidenced by the FDA approval of venetoclax in 2016. Researchers have redoubled their… read more here.
Keywords: selective bcl; bcl degradation; treatment; cancer treatment ... See more keywords
From basic apoptosis discoveries to advanced selective BCL-2 family inhibitors
Sign Up to like & getrecommendations! Published in 2017 at "Nature Reviews Drug Discovery"
DOI: 10.1038/nrd.2016.253
Abstract: Members of the B cell lymphoma 2 (BCL-2) gene family have a central role in regulating programmed cell death by controlling pro-apoptotic and anti-apoptotic intracellular signals. In cancer, apoptosis evasion through dysregulation of specific BCL-2… read more here.
Keywords: apoptosis; bcl family; family; selective bcl ... See more keywords